Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies

@inproceedings{Anker2015UlaritideFT,
  title={Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies},
  author={Stefan D. Anker and Piotr P Ponikowski and Veselin Mitrovi{\'c} and William Franklin Peacock and Gerasimos Filippatos},
  booktitle={European heart journal},
  year={2015}
}
The short- and long-term morbidity and mortality in acute heart failure is still unacceptably high. There is an unmet need for new therapy options with new drugs with a new mode of action. One of the drugs currently in clinical testing in Phase III is ularitide, which is the chemically synthesized form of the human natriuretic peptide urodilatin. Urodilatin is produced in humans by differential processing of pro-atrial natriuretic peptide in distal renal tubule cells. Physiologically… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Effects of ularitide on the endothelin and aldosterone system, cardiac troponins, and renal function in acute decompensated heart failure

  • V Mitrovic, H Luss, PM Seferovic, D Simeunovic, AD Ristic, S Felix
  • Eur J Heart Fail 2013;15(Suppl. 1):S10
  • 2013
1 Excerpt

Plasma and urinary cGMP in heart failure in relation to natriuretic peptides (Abstract 949)

  • A Jovanovic, S Lehinant, WG Forssmann, C Hamm, V. Mitrovic
  • Eur J Heart Fail Suppl 2010;9(Suppl 1):S168
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…